Advanced Filters
noise

Immune Thrombocytopenia Clinical Trials

A listing of Immune Thrombocytopenia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 88 clinical trials
C Chaoke Bu, Doctor

Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia

This study is a clinical study initiated by single-arm, single-center, multiple administration researchers. The main purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells in refractory ITP subjects. The subjects voluntarily signed the informed consent form, and after the evaluation of the screening period …

4 - 75 years of age All Phase N/A
M Min Yang, MD

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.

18 - 60 years of age All Phase 1
M Ming Hou, PhD

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients with Chronic Primary Immune Thrombocytopenia

18 - 80 years of age All Phase 3

The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

to investigate efficacy and safety evaluation of bortezomib in patients with relapsed/refractory immune thrombocytopenia

19 years of age All Phase 2
W Wei Qin, doctor

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19 CAR NK cells (KN5501) in patients with refractory immune thrombocytopenia. 9 patients are planned to be enrolled in the dose-escalation trial (9×10^9 cells, 13.5×10^9 cells). The primary objective of the study is to evaluation …

18 - 65 years of age All Phase N/A
M Mohsin Elalfy, Professor

Management of Children With Persistent ITP, A Novel Approach

The goal of this clinical trial is to learn if mini-pool intravenous immunoglobulin (IVIG) is a safe and effective treatment for children with persistent immune thrombocytopenia (ITP). ITP is a condition that causes low platelet levels and increases the risk of bleeding. The main questions this study aims to answer …

1 - 10 years of age All Phase N/A
Z Zhenyu Yan, Doctor

A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia

The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP). The main questions the study aims to answer are: To evaluate the safety and tolerability of CID-103 in subjects with …

18 - 65 years of age All Phase 1/2
Y Yunfeng Cheng

The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP

The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus prednisone (Pred) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults. It will also learn about the safety of HCQ plus Pred. The main questions it aims to answer are: Does HCQ plus Pred …

15 - 99 years of age All Phase N/A
Y Yunfeng Cheng

The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP

The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus dexamethasone (DEX) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults. It will also learn about the safety of HCQ plus DEX. The main questions it aims to answer are: Does HCQ plus DEX …

15 - 75 years of age All Phase N/A
Y Yunfeng Cheng

The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP

The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus thrombopoietin receptor agonists (TPO-RA) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults. It will also learn about the safety of HCQ plus TPO-RA. The main questions it aims to answer are: Does HCQ …

15 - 99 years of age All Phase N/A

Simplify language using AI